T-Cell Activation Marker Expression on Tumor-infiltrating Lymphocytes as Prognostic Factor in Cutaneous Malignant Melanoma

2006 ◽  
Vol 2006 ◽  
pp. 46-47
Author(s):  
D.M. Jukic
Keyword(s):  
T Cell ◽  
Malignant Melanoma ◽  
Prognostic Factor ◽  
T Cell Activation ◽  
Cell Activation ◽  
Tumor Infiltrating Lymphocytes ◽  
Cutaneous Malignant Melanoma ◽  
Activation Marker ◽  
Cell Activation Marker ◽  
Infiltrating Lymphocytes

The T cell activation marker CD150 can be used to identify alloantigen-activated CD4+25+ regulatory T cells

2004 ◽  
Vol 227 (2) ◽  
pp. 129-139 ◽  
Author(s):  
Meghen B. Browning ◽  
Jeffrey E. Woodliff ◽  
Marja C. Konkol ◽  
Nirupma T. Pati ◽  
Soumitra Ghosh ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Regulatory T Cells ◽  
T Cell Activation ◽  
Cell Activation ◽  
Activation Marker ◽  
Cell Activation Marker

scholarly journals T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes

2018 ◽  
Vol 24 (13) ◽  
pp. 1715-1724 ◽  
Author(s):  
Yu Yi M Wong ◽  
Roos M van der Vuurst de Vries ◽  
E Daniëlle van Pelt ◽  
Immy A Ketelslegers ◽  
Marie-José Melief ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
T Cell ◽  
T Cell Activation ◽  
Predictive Value ◽  
Cell Activation ◽  
Oligoclonal Bands ◽  
Activation Marker ◽  
Cell Activation Marker ◽  
Definite Multiple Sclerosis ◽  
Clinically Definite Multiple Sclerosis

Background: Cerebrospinal fluid (CSF) levels of T-cell activation marker soluble CD27 (sCD27) are associated with subsequent disease activity after a first attack of suspected MS in adults. The predictive value for disease course in children with acquired demyelinating syndromes (ADS) is unknown. Objectives: To assess the predictive value of sCD27 levels for clinically definite multiple sclerosis (CDMS) diagnosis in childhood ADS. Methods: Children <18 years with a first demyelinating event were prospectively included and followed. Soluble CD27 was determined in CSF using an enzyme-linked immunosorbent assay (ELISA). Cox regression analyses were used to calculate hazard ratios (HRs) for CDMS. Results: A total of 94 ADS children were included (ADS with encephalopathy (ADS+) n = 33 and ADS without encephalopathy (ADS–) n = 61). Of the 61 ADS– children, 21 (48%) were diagnosed with CDMS during follow-up. At baseline, sCD27 levels were higher in patients with a future CDMS diagnosis ( n = 29) than in monophasic ADS+ ( n = 30), monophasic ADS– ( n = 28) and relapsing non-MS patients ( n = 7; p < 0.001). In ADS– patients, sCD27 was associated with CDMS (HR = 1.8 per 100 U/mL increase in sCD27 levels, p = 0.031), after adjustments for age, oligoclonal bands and the presence of dissemination in space on baseline magnetic resonance imaging (MRI). Conclusion: CSF sCD27 levels at first attack of demyelination were associated with CDMS diagnosis in children. This makes sCD27 a potential clinically relevant quantitative marker when performing routine CSF diagnostics.

Association of minimally invasive colorectal resection with elevated levels of plasma B7 homolog 1 (B7-H1) during the first month after surgery and effect on immune suppression and growth of residual metastases.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 602-602
Author(s):  
Hmc Shantha Kumara ◽  
Erica Pettke ◽  
Carl S Winkler ◽  
Sandhu K Jaspreet ◽  
Xiaohong Yan ◽  
...  
Keyword(s):  
T Cell ◽  
T Cell Activation ◽  
Cell Activation ◽  
Tumor Infiltrating Lymphocytes ◽  
Wilcoxon Test ◽  
Intestinal Epithelial ◽  
The Mean ◽  
Infiltrating Lymphocytes ◽  
Cell Effector Function ◽  
Cell Effector

602 Background: The co-stimulatory molecule B7 homolog 1 (B7-H1) is a ligand for PD-1 which is an immunoinhibitory receptor of activated lymphocytes. PD-1 expression is upregulated on tumor infiltrating lymphocytes (TILs), and B7-H1 expressed on cancer cells may inhibit T-cell activation and proliferation. B7-H1 is also expressed on endothelial (EC) and intestinal epithelial cells as well as activated macrophages. B7H1 in EC is rapidly induced by IFN-gamma and TNF. B7-H1 silencing with siRNA inhibits tumor cell proliferation/invasion. B7H1 expression in keratinocytes (KC) directly downregulates CD8(+) T-cell effector function via PD-1 binding at sites of inflammation. Shed B7-H1 can be found in the blood. Surgery’s impact on plasma B7H1 levels is unknown. This study’s purpose was to evaluate plasma B7H1 levels during the first month after MICR for colorectal (CRC). Methods: MICR CRC patients in an IRB approved data/plasma bank with adequate plasma available were eligible. Clinical and pathological data were reviewed. Blood samples were collected preoperatively (PreOp) and at 6 post-operative (Postop) time points (POD 1, 3, 7-13, 14-20, 21-27, 28-41). B7-H1 levels were analyzed in duplicate using ELISA. The Wilcoxon test was used for analysis. Results: 88 CRC patients who had a MICR met inclusion criteria (28% rectal and 62% colon lesions). The mean PreOp B7-H1 level was 51.9±20.9 pg/ml. Significantly elevated mean plasma levels were noted on POD1 (64.9±24.2 pg/ml, n = 86, p = < 0.0001), POD3 (67.3±24.6 pg/ml, n= 72, p = < 0.0001), POD7-13 (69.2±22.6 pg/ml, n = 65, p = < 0.0001), POD14-20 (72.5±28.9 pg/ml, n=23,p=0.001), POD 21-27 (79.4±66.6 pg/ml, n = 13, p = 0.001), and on POD 28-41 (56.3 ±22.7 pg/ml, n = 20, p =0.02), when compared to PreOp levels. Conclusions: Plasma B7-H1 levels are elevated for over a month after MICR for CRC. The etiology of the early increase may be the acute inflammatory response whereas late elevations may be related to wound healing-related tissue remodeling. Elevated plasma B7-H1 may suppress TIL’s which may result in increased tumor growth. Further studies are warranted.

Sign in / Sign up

Export Citation Format

Share Document